Discodermolide
Alternative Names: XAA 296; XAA 296ALatest Information Update: 19 Jul 2010
At a glance
- Originator Harbor Branch Oceanographic Institution
- Developer Novartis
- Class Antineoplastics; Lactones
- Mechanism of Action Apoptosis stimulants; Immunosuppressants; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2010 Discontinued - Phase-I for Cancer in USA (IV-infusion)
- 25 May 2005 Suspended - Phase-I for Cancer in USA (IV-infusion)
- 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the pharmacokinetics section